Sex mismatch in BMT (X and Y)

Reproductive

Report in 72Hrs

At Home

No Fasting Required

Details

FISH test for donor vs recipient sex.

₹4,440₹6,343

30% OFF

Sex Mismatch in BMT (X and Y) - Comprehensive Medical Test Guide

Why is it done?
- Detection of donor-recipient sex mismatch in bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT) using sex chromosome analysis (X and Y chromosome markers)
- Monitoring engraftment and chimerism status when donor and recipient are of opposite biological sex
- Assessing the success of bone marrow engraftment by detecting the presence of donor-derived cells in recipient circulation
- Differentiating between autologous and allogeneic transplant outcomes when sex differs between donor and recipient
- Detecting graft failure, graft rejection, or mixed chimerism post-BMT
- Performed at multiple timepoints: pre-transplant (baseline), immediately post-transplant (7-14 days), and at regular intervals (1, 3, 6, and 12 months post-transplant)
- Used clinically in patients undergoing allogeneic BMT/HSCT for hematologic malignancies, aplastic anemia, or immunodeficiency disorders
Normal Range
- Pre-transplant (Baseline): 100% recipient cells (if female recipient: XX genotype; if male recipient: XY genotype)
- Post-transplant Complete Engraftment (Expected Normal): ≥95% donor cells; for sex-mismatched BMT, this represents complete conversion to donor sex chromosome profile (e.g., XX to XY if male donor, or XY to XX if female donor)
- Borderline/Mixed Chimerism: 5-95% donor cells present (presence of both donor and recipient sex chromosomes detected)
- Graft Failure/Rejection: <5% donor cells or 100% recipient cells (absence of donor sex chromosome markers, persistence of recipient chromosome profile)
- Units of Measurement: Percentage (%) of donor cells; qualitative detection of X and Y chromosome presence/absence
Interpretation
- Complete Donor Engraftment (≥95% donor cells):
  - Indicates successful bone marrow engraftment with complete hematopoietic reconstitution from donor cells
  - In sex-mismatched BMT, complete conversion of recipient sex chromosome to donor pattern (e.g., female recipient's XX pattern replaced by male donor's XY pattern)
  - Typically achieved within 2-4 weeks post-transplant; excellent prognosis for sustained engraftment
- Mixed Chimerism (5-95% donor cells):
  - Presence of both donor and recipient cells detected; both sex chromosome patterns observable
  - Indicates incomplete engraftment, slow engraftment kinetics, or development of mixed chimerism over time
  - May occur in patients with good graft tolerance, those receiving T-cell depleted grafts, or in certain disease settings
  - Requires close monitoring for potential graft rejection or relapse depending on clinical context
- Graft Failure/Rejection (<5% donor cells or 100% recipient cells):
  - Complete absence or minimal presence of donor cells; only recipient sex chromosome pattern detected
  - Indicates primary graft failure (failure to achieve initial engraftment) or secondary graft rejection (loss of previously established donor cells)
  - Associated with poor clinical outcome and increased risk of disease relapse; requires urgent intervention such as re-transplantation or immunotherapy
- Factors Affecting Interpretation:
  - Type of graft preparation (unmanipulated vs. T-cell depleted)
  - Conditioning regimen intensity (myeloablative vs. reduced intensity)
  - GVHD prophylaxis regimen and timing
  - Timing of sample collection post-transplant (early vs. late timepoints)
  - Underlying disease (hematologic malignancy, aplastic anemia, immunodeficiency)
  - HLA matching status between donor and recipient
  - Presence of GVHD post-transplant (may correlate with enhanced engraftment)
Associated Organs
- Primary Organ System - Hematopoietic System:
  - Bone marrow (source of transplanted hematopoietic stem cells)
  - Peripheral blood (site of sampling for chimerism analysis)
  - Blood-forming organs and circulating blood cells (white blood cells, red blood cells, platelets)
- Diseases Associated with Abnormal Results:
  - Acute myeloid leukemia (AML) - undergoing BMT for primary disease
  - Acute lymphoblastic leukemia (ALL) - risk of relapse if graft failure occurs
  - Chronic myeloid leukemia (CML) - engraftment status critical for disease control
  - Severe aplastic anemia (SAA) - graft failure may necessitate re-transplantation
  - Myelodysplastic syndrome (MDS) - requiring stem cell transplantation for treatment
  - Lymphomas (Hodgkin and non-Hodgkin) - candidates for salvage BMT
  - Multiple myeloma - undergoing high-dose chemotherapy with autologous or allogeneic transplant
  - Immunodeficiency disorders (SCID, Wiskott-Aldrich syndrome) - requiring immune reconstitution
- Potential Complications Associated with Abnormal Results:
  - Primary graft failure - complete failure to achieve initial engraftment; requires re-transplantation
  - Secondary graft rejection - loss of engraftment after initial successful establishment
  - Disease relapse - malignant cells recurrence in patients with hematologic malignancies
  - Infections due to inadequate immune reconstitution from failed engraftment
  - Graft-versus-host disease (GVHD) - can paradoxically indicate adequate engraftment and graft function
  - Hemorrhage and organ failure from cytokine-mediated injury in setting of graft failure
  - Secondary malignancies from conditioning regimens in setting of sustained engraftment
Follow-up Tests
- Routine Follow-up Testing for Chimerism Monitoring:
  - Repeat sex chromosome analysis (FISH for X/Y or PCR-based methods) at scheduled intervals: post-transplant day 7-14, day 30, day 60-100, day 180, and 1 year post-transplant
  - More frequent monitoring if initial tests show delayed engraftment or graft failure
- Additional Chimerism Assessment Tests:
  - STR (short tandem repeat) analysis - polymerase chain reaction based method to assess donor/recipient cell proportions
  - FISH (fluorescence in situ hybridization) analysis - alternative method for sex chromosome assessment in males (XY) and females (XX)
  - Digital PCR or qPCR - quantitative assessment of donor/recipient cell percentages
  - Next-generation sequencing (NGS) - high-resolution assessment of chimerism status
- Hematologic Tests for Engraftment Assessment:
  - Complete blood count (CBC) - assess neutrophil, platelet, and red blood cell recovery post-transplant
  - Bone marrow aspiration and biopsy - morphologic assessment of hematopoietic recovery and cellularity
  - Flow cytometry - assessment of immune reconstitution and T-cell, B-cell, NK cell recovery
- Disease-Specific Monitoring Tests:
  - Cytogenetics and molecular testing - detection of minimal residual disease (MRD) in patients with hematologic malignancies
  - BCR-ABL PCR testing - monitoring for disease recurrence in chronic myeloid leukemia patients
  - Immunoglobulin and T-cell receptor rearrangement analysis - assessment of hematologic malignancy burden
- Monitoring for Complications:
  - GVHD assessment - clinical and histologic evaluation for acute and chronic graft-versus-host disease
  - Infectious disease serology and cultures - surveillance for opportunistic infections post-transplant
  - Organ function monitoring - liver, kidney, and cardiac assessments per transplant protocols
Fasting Required?
- No - Fasting is not required for sex chromosome analysis and chimerism testing
- Sample Collection:
  - Peripheral blood draw - typically 5-10 mL of whole blood collected in EDTA (lavender-top) tube for DNA extraction
  - Bone marrow aspirate/biopsy - may be collected simultaneously if morphologic assessment is needed
  - Sample should be transported promptly to laboratory (within 24 hours) at room temperature
- Patient Preparation Requirements:
  - No special fasting requirements - patient may eat and drink normally before blood collection
  - Timing of sample collection is more critical than fasting status - samples should be drawn at specified post-transplant timepoints
  - Patient should have informed consent and understand the purpose of testing
- Medications to Avoid:
  - No specific medications need to be withheld before this test
  - Continue all post-BMT medications including GVHD prophylaxis and immunosuppression as prescribed

How our test process works!